Switch treatment to ICLUSIG® (ponatinib) at the critical moment

When TKI resistance or intolerance occurs, think ICLUSIG—the only third-generation, BCR-ABL1 inhibitor with proven efficacy in CML and Ph+ ALL, regardless of mutation status—including T315I1,2

Category 2A, preferred NCCN recommendation.

Ponatinib is the preferred treatment option for patients with a T315I mutation.  It is also a treatment option for CP-CML with resistance or intolerance to at least two prior TKIs, or for patients with AP-CML or BP-CML for whom no other TKI is indicated.3

Discover the types of patients appropriate for ICLUSIG

ICLUSIG may benefit adult patients with chronic, accelerated, or blast phase CML who are resistant to TKIs.1

Optimized, response-based dosing strategy for CP-CML

A starting dose of 45 mg can be reduced to 15 mg once patients achieve ≤1% BCR::ABL1IS.3

ICLUSIG efficacy for Ph+ ALL

For TKI resistant/intolerant Ph+ ALL, ICLUSIG is the only TKI to show activity against all known single-point mutations, including T315I.1

ICLUSIG (ponatinib) is an FDA-approved TKI for adult patients with1:

  • CP-CML with resistance or intolerance to at least 2 prior TKIs
  • T315I-positive CML (CP-, AP-, and BP-) and Ph+ ALL
  • AP- or BP-CML or Ph+ ALL for whom no other TKIs are indicated

AP-CML=accelerated phase chronic myeloid leukemia; BP-CML=blast phase chronic myeloid leukemia; CML=chronic myeloid leukemia; CP-CML=chronic phase chronic myeloid leukemia; Ph+ ALL=Philadelphia chromosome positive acute lymphoblastic leukemia; TKI=tyrosine kinase inhibitor.

Limitations of use:

ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.